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Abstract
AIM: To investigate intestinal alkaline phosphatase (iAP) 
in the intestinal mucosa of children with inflammatory 
bowel disease (IBD). 
METHODS: Colonic biopsy samples were taken from 
15 newly diagnosed IBD patients and from 10 healthy 
controls. In IBD patients, specimens were obtained 
both from inflamed and non-inflamed areas. The iAP 
mRNA and protein expression was determined by 
reverse transcription-polymerase chain reaction and 
Western blotting analysis, respectively. Tissue localiza-
tion of iAP and Toll-like receptor (TLR) 4 was investi-
gated by immunofluorescent staining. 
RESULTS: The iAP protein level in the inflamed muco-
sa of children with Crohn’s disease (CD) and ulcerative 
colitis (UC) was significantly decreased when compared 
with controls (both P  < 0.05). Similarly, we found a 
significantly decreased level of iAP protein in the in-
flamed mucosa in CD compared with non-inflamed 
mucosa in CD (P  < 0.05). In addition, the iAP protein 
level in inflamed colonic mucosa in patients with UC 
was decreased compared with non-inflamed mucosa in 
patients with CD (P  < 0.05). iAP protein levels in the 
non-inflamed mucosa of patients with CD were similar 
to controls. iAP mRNA expression in inflamed colonic 
mucosa of children with CD and UC was not significant-
ly different from that in non-inflamed colonic mucosa 
with CD. Expression of iAP mRNA in patients with non-
inflamed mucosa and in controls were similar. Co-local-
ization of iAP with TLR4 showed intense staining with 
a dotted-like pattern. iAP was present in the inflamed 
and non-inflamed mucosa of patients with CD, UC, and 
in control biopsy specimens, irrespective of whether 
it was present in the terminal ileum or in the colon. 
However, the fluorescent signal of TLR4 was more pro-
nounced in the colon compared with the terminal ileum 
in all groups studied.
CONCLUSION: Lower than normal iAP protein levels 
in inflamed mucosa of IBD patients may indicate a role 
for iAP in inflammatory lesions in IBD. Based on our 
results, administration of exogenous iAP enzyme to pa-
tients with the active form of IBD may be a therapeutic 
option.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
The etiology of  inflammatory bowel disease (IBD), in-
cluding ulcerative colitis (UC) and Crohn’s disease (CD), 
remains unclear. It is hypothesized that, in genetically sus-
ceptible individuals, inappropriate and ongoing activation 
of  a mucosal immune response against luminal antigens 
is a major cause of  the inflammation[1,2]. In active IBD, 
the tolerance towards the resident intestinal flora is de-
creased. The balance between protective and commensal 
luminal bacterial species is lost and, due to increased mu-
cosal permeability and insufficient mucosal clearance, the 
commensal flora and pathogenic bacteria enter into the 
lamina propria and destructive inflammatory responses 
are unavoidable[3-6]. This prompts an exaggerated immune 
response with the activation of  the two arms of  mucosal 
immune system, the innate and adaptive elements[7,8]. 
The activation of  the innate immune system heav-
ily depends on the recognition of  microbes by pattern 
recognition receptors such as Toll-like receptors (TLRs). 
The TLR family consists of  13 members, and each has 
different type of  ligands. One of  them is TLR4, which is 
responsible for recognition of  lipopolysaccharide (LPS), 
a principal component of  the bacterial outer membrane. 
Uncontrolled activation of  TLR4 may lead to the loss of  
mucosal barrier integrity, aggravation of  the inflamma-
tory response within the gut epithelial mucosa, increased 
expression of  TLR-ligands and tumorigenesis[9-13]. Pre-
viously, we found increased TLR4 protein and mRNA 
levels in the inflamed mucosa of  children with IBD and 
celiac disease[14,15]. 
An increasing body of  evidence also supports the 
regulatory role of  intestinal alkaline phosphatase (iAP) in 
TLR activation. iAP is expressed on the apical surface of  
enterocytes and exists in membrane-bound and soluble 
forms[16]. iAP plays an essential role in the inactivation 
of  LPS through dephosphorylation of  its lipid A moiety, 
thus generating a non-toxic monophosphoryl section. 
This dephosphorylated monophosphoryl lipid A is not 
able to form a complex with TLR4[17,18]. 
There is only one human study where expression of  
iAP (mRNA) in adult IBD patients was analyzed, and 
lower than normal iAP mRNA expression was found 
in epithelial specimens[19]. It should be noted, however, 
that no data on the level of  iAP protein in IBD mucosa 
is available. The aim of  our study was to investigate iAP 
protein and mRNA levels in affected and non-affected 
colon mucosa of  children with newly diagnosed IBD. In 
addition, our secondary aim was to determine the local-
ization of  iAP enzyme with TLR4. 
MATERIALS AND METHODS
Patients and colonic biopsies
Ten children (7 boys, 3 girls; median age: 10.5 years, 
range: 1.5-15 years) with newly diagnosed CD, 5 children 
(3 boys, 2 girls; median age: 11 years, range: 6-17 years) 
with newly diagnosed UC, and 10 control children (5 
boys, 5 girls; median age: 9.5 years, range: 1.5-16 years) 
were enrolled in the study (Table 1). IBD was diagnosed 
according to the Porto criteria[20,21]. The presenting symp-
toms in CD were perianal fistula, hematochezia, abdomi-
nal pain, diarrhea-bloody diarrhea, or anemia. All of  the 
patients later diagnosed with UC had hematochezia, and 
some had abdominal pain and weight loss. Colonic bi-
opsy samples were taken from macroscopically inflamed 
and non-inflamed sites of  the colonic mucosa in children 
with CD. As each UC children had pancolitis, only in-
flamed mucosa was obtained from UC patients (Table 1). 
The activity score was calculated by means of  the Pediat-
ric Crohn’s Disease Activity Index (PCDAI) and Pediatric 
Ulcerative Colitis Activity Index (PUCAI)[22,23]. Measuring 
disease activity in pediatric CD is based on disease history 
(abdominal pain, stools per day and general well-being), 
laboratory findings, weight, abdominal and perianal ex-
amination, extra-intestinal manifestations, and growth 
rate[24]. PUCAI requires no laboratory measurements[25]. 
The mean PCDAI of  our patients was 33.75, and the 
mean PUCAI was 35. This means that both groups had 
moderate-to-severe disease activity. Control children were 
referred to the outpatient clinic with rectal bleeding, con-
stipation or weight loss. Colonoscopy was part of  their 
diagnostic procedure and the biopsy specimens showed 
normal macroscopic appearance and histology. Written 
informed consent was obtained from parents prior to the 
procedure, and the study was approved by the Semmel-
weis University Regional and Institutional Committee and 
Research Ethics. 
RNA isolation and real-time polymerase chain reaction 
Total RNA was isolated from the colonic biopsy samples 
by RNeasy Total RNA Isolation Kit (Qiagen GmbH, 
Hilden, Germany), according to the instructions of  the 
manufacturer. One μg of  total RNA was reverse-tran-
scribed and iAP mRNA expressions were determined by 
real-time polymerase chain reaction (PCR) on Light Cy-
cler480 (Roche Diagnostics, Mannheim, Germany). PCRs 
were performed containing RealTime ready Catalog As-
say primer (Roche Diagnostics), Light Cycler 480 Probes 
Master (Roche Diagnostics, Mannheim, Germany), and 
cDNA. Conditions for iAP mRNA measurements: one 
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cycle, 95 ℃, 10 min (denaturation), followed by several 
cycles at 95 ℃, 10 s and 30 s, 72 ℃ 1 s (annealing and 
extension). The mRNA expression of  glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as internal control 
was determined using Brillant Ⅱ Fast SYBR Green quan-
titative polymerase chain reaction Master Mix (Stratagene, 
Cedar Creek, TX, United States), PCR primers (Forward: 
5’-CAC CAC CAT GGA GAA GGC TG-3’; Reverse: 
5’-GTG ATG GCA TGG ACT GTG-3’, Invitrogen, 
CA, United States) and cDNA. Conditions for GAPDH: 
one cycle, 95 ℃, 2 min, 50 cycles at 95 ℃ 20 s and 60 ℃, 
40 s. Results were analyzed by Light-Cycler software 480 
(Roche Diagnostics). 
Protein isolation and Western blotting 
Colonic biopsy specimens were homogenized in lysing 
solution, and protein concentrations were determined 
by DC Protein Assay (Bio-Rad Laboratories, Hercules, 
CA, United States); 0.5 µg protein from each sample was 
separated by 10% sodium dodecyl sulfate-polyacrilamide 
gel electrophoresis (120 V, 40 mA, 120 min) (PenguinTM 
Dual-Gel Water Cooler Systems, Owl, NH, United States) 
and transferred to nitrocellulose membrane (GE Health-
care, Little Chalfont, United Kingdom) (70 V, 220 mA, 
120 min) (MiniTankTM electroblotter, Owl). Membranes 
were blocked in 1% non-fat dry milk solution (1 h) and 
incubated with iAP specific rabbit polyclonal antibody 
(1:1000, 1 h) (AbCam, Cambridge, United Kingdom). 
Equal protein loading was confirmed by β-actin specific 
(C-11) goat polyclonal IgG antibody (1:100) (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, United States). Per-
oxidase-conjugated secondary anti-rabbit IgG or donkey 
anti-goat IgG antibodies (1:2000, 30 min) (Santa Cruz 
Biotechnology Inc.) were used. Immunoreactive bands 
were visualized using the enhanced chemiluminescence 
Western blotting detection protocol (GE Healthcare). 
Bands were analyzed with software Image J. 1.42q (Na-
tional Institutes of  Health, United States). The values 
were expressed as relative optical density. 
Immunofluorescent staining 
Biopsy samples were snap-frozen, embedded in Shan-
don cryomatrix (ThermoElectron Co., Waltham, United 
States), cut to 3-4 μm slides and double incubated with 
TLR4 specific goat polyclonal antibody and iAP specific 
rabbit polyclonal antibody (1:100, 1 h) (Abcam Plc). Sec-
ondary antibodies were Alexa Fluor 488 donkey anti-goat 
and Alexa Fluor 568 goat anti-rabbit antibodies (Invit-
rogen). Zeiss LSM 510 Meta confocal laser scanning mi-
croscope (Carl Zeiss, Jena, Germany) was used with 20 × 
Plan Apochromat (NA = 0.8) and 63 × Plan Apochromat 
oil immersion differential interference contrast objectives 
(NA = 1.4).
Statistical analysis
Data were analyzed using Statistica 7.0 software (StatSoft 
Inc., Tulsa, OK, United States). After testing the nor-
mality with Shapiro-Wilk’s test, non-parametric Mann-
Whitney U test was used. Data were considered statisti-
cally significant if  P ≤ 0.05, and expressed as mean ± 
standard deviation.
RESULTS
iAP protein levels 
Western blotting analysis revealed one distinct band at 
60 kDa. The iAP protein level in the inflamed mucosa 
of  children with CD and UC was lower by 22% and 
20%, respectively, compared with controls (P < 0.05). We 
found a lower iAP protein level in the inflamed mucosa 
in CD compared with non-inflamed mucosa in CD (P 
< 0.05). The iAP protein level in the inflamed colonic 
mucosa in UC patients was decreased by 24% compared 
with non-inflamed mucosa in CD patients (P < 0.05) 
(Figure 1). iAP protein levels in the non-inflamed mucosa 
of  patients with CD were normal. 
iAP mRNA expression 
iAP mRNA expression in inflamed and non-inflamed 
colonic mucosa in IBD was comparable with that in con-
trols (Figure 2). 
Mucosal localization of iAP and TLR4 
The distribution of  iAP was restricted to the epithelial 
3256 July 7, 2012|Volume 18|Issue 25|WJG|www.wjgnet.com
Table 1  Clinical characteristics of newly diagnosed patients 
with Crohn's disease and ulcerative colitis
Patient Form 
of IBD 
Gender Age 
(yr) 
Main complaints 
at presentation 
Activity 
score 
Duration 
(symptoms) (mo) 
1 CD F 15 Perianal fistula 25 1 
2 CD M   4 Hematochezia 20 3 
3 CD M 11 Abdominal 
pain, diarrhea
45 2 
4 CD F   9 Bloody 
diarrhoea
25 2 
5 CD F   4 Diarrhoea, 
anaemia
30 3 
6 CD M 14 Hematochezia 50 6 
7 CD F  1.5 Bloody 
diarrhoea
35    1.5 
8 CD M 11 Bloody 
diarrhoea
20 2 
9 CD M 12 Diarrhoea, 
anaemia
35 3 
10 CD M 10 Weight loss, 
diarrhea
   52.5 1.5 
11 UC F 12 Hematochezia, 
abdominal pain
20 4 
12 UC M   9 Hematochezia, 
anaemia
35 1 
13 UC M 17 Hematochezia, 
abdominal pain
25 7 
14 UC F 12 Hematochezia, 
weight loss
55 4 
15 UC M   6 Hematochezia 40    2.5 
The activity score was calculated by means of pediatric Crohn’s disease 
activity index and pediatric ulcerative colitis activity index. IBD: 
Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; 
M: Male; F: Female.
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mucosa and LPS derived from the bacterial flora[28,29]. 
In the present study, we obtained data regarding the 
protein level, mRNA expression and localization of  iAP 
in the intestinal mucosa of  children with IBD. Lower than 
normal iAP levels were observed in the inflamed mucosa 
of  CD and UC patients. 
Previously it was hypothesized that the altered LPS-
dephosphorylating activity may be a consequence of  
decreased iAP activity. We think that, in accordance with 
Tuin et al[19], our observations also suggest that iAP has a 
role in the pathogenesis of  IBD. Decreased iAP levels in 
the inflamed mucosa may be associated with decreased 
LPS detoxification and, consequentially, with increased 
TLR4 activation. On the other hand, we found no signifi-
cant difference in iAP mRNA expression that may indi-
cate a possible role of  posttranscriptional regulation. 
Tuin et al[19]demonstrated decreased iAP mRNA ex-
pression in pretreated CD patients compared with con-
trols. However, it should be noted that, in this study, more 
than half  of  the patients received immunosuppressive 
drugs such as infliximab, methotrexate, corticosteroids, 
and thiopurine at the time of  sample collection, which 
may influence iAP mRNA synthesis[30]. The unique feature 
of  our study is the investigation of  children without prior 
immunomodulatory therapy, hence, our results can be 
considered as characteristic for IBD. 
Previously, we have demonstrated increased TLR4 
mRNA expression and protein levels in the inflamed 
colonic mucosa of  children with IBD[14]. Therefore, the 
finding that iAP and TLR4 are co-localized, is particularly 
important from two aspects. First, it supports a linked 
role of  iAP in the maintenance of  mucosal integrity 
both in healthy and in diseased subjects. Second, the 
lower than normal iAP in the presence of  a higher than 
surface of  the colonic and terminal ileal mucosa in each 
group. No fluorescent signal was detected in Lieberkühn 
crypt cells, in goblet cells, and in lamina propria immune 
cells. The co-localization of  iAP with TLR4 showed 
intense staining with a dotted-like pattern. iAP was pres-
ent in inflamed and non-inflamed mucosa of  patients 
with CD, UC, and in control specimens irrespective of  
whether it was present in the terminal ileum or in the co-
lon. However, the fluorescent TLR4 signal was more pro-
nounced in the colon compared with the terminal ileum 
in all groups (Figure 3). 
DISCUSSION
A dysregulated immune response, involving the innate 
immunity of  the intestinal mucosa plays a role in the 
pathomechanism of  IBD. The maintenance of  microbiota 
and host is supported by the balance of  microbiota and im-
mune activation that may be disturbed in IBD[26]. Previously 
we and others showed that activation of  TLR4 by bacterial 
lipopolysaccharide contributes to disease progression[14,27]. 
Recently, in connection with LPS-activated TLR4, a 
new enzyme, iAP has received increasing attention as a 
factor responsible for mucosal defense. iAP dephosphor-
ylates and detoxifies LPS and, hence, generates an inac-
tive, non-toxic form. This may be one of  the key factors 
why dephosphorylated LPS is unable to bind to TLR4 
and the innate immune system is not triggered. iAP may 
control the interaction between TLR4 in the intestinal 
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Figure 1  Protein levels of intestinal alkaline phosphatase in the colonic 
mucosa of children with newly diagnosed Crohn’s disease, ulcerative 
colitis and controls. A: Western blotting analysis of the colonic biopsy speci-
mens using intestinal alkaline phosphatase (iAP)-specific antibody reveals 
one distinct band at 60 kDa; B: Data for protein levels of iAP were obtained by 
computerized analysis of the Western blottings and expressed as median inter-
quartile range. Analysis of significance was performed by the Mann-Whitney U 
test. aP < 0.05 vs control; dP < 0.01 vs non-inflamed CD; eP < 0.05 vs UC. CD: 
Crohn’s disease; UC: Ulcerative colitis. 
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Figure 2  Intestinal alkaline phosphatase mRNA expression in the colonic 
mucosa of children with newly diagnosed Crohn’s disease, ulcerative 
colitis and controls. iAP mRNA expression data were obtained by computer-
ized analysis of PCR products. Optical density was corrected according to 
that of GAPDH. Data are expressed as median interquartile range. Analysis of 
significance was performed by Mann-Whitney U test. GAPDH: Glyceraldehyde-
3-phosphate dehydrogenase; PCR: Polymerase chain reaction; iAP: Intestinal 
alkaline phosphatase; CD: Crohn’s disease; UC: Ulcerative colitis. 
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normal TLR4 expression might indicate an imbalance in 
iAP/TLR4 that would result in an increased susceptibility 
of  the mucosa to LPS. Indeed, this mechanism is already 
demonstrated in animal models of  induced colitis. Our 
results are the first to indicate the presence of  this phe-
nomenon in man. 
The current management of  IBD consists of  conven-
tional therapy, but severe therapy-resistant cases require 
more powerful therapies, such as biological treatment[31]. 
Therapeutic manipulation to restore the balance of  mi-
croflora may have a strong impact on mucosal healing 
of  IBD[32]. In animal models of  dextrane sodium sulfate 
(DSS)-induced colitis, exogenously administered iAP 
improved the signs of  colitis both macroscopically and 
microscopically[33]. Microscopic injury scores of  DSS-
induced colitis in iAP-knockout mice were much higher 
than in the wild-type group, which may reveal the muco-
sal defense role of  iAP[34]. In a human study performed 
in adult subjects a 7-d course of  iAP products decreased 
the activity index of  therapy-resistant UC patients[35]. Oral 
administration of  iAP may have a beneficial effect in the 
case of  severe intestinal epithelial damage[36]. Our results 
obtained in a pediatric population might indicate a similar 
approach may be of  benefit in children with IBD. 
In summary, to the best of  our knowledge, this is the 
first demonstration of  a decrement in the iAP enzyme 
in the mucosa of  patients with IBD. A decreased level 
of  iAP with reduced LPS-detoxifying capacity could be 
responsible for increased bacterial passage across the 
intestinal mucosa of  patients with IBD, and this may 
play an important role in pathogenesis. In addition, co-
localization of  iAP and TLR4 was demonstrated in the 
epithelial compartment. Based on our results, administra-
tion of  exogenous iAP enzyme to patients with active 
form of  IBD may be a supplemental therapeutic option. 
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